EINSTEIN et al.

Appl. No. 10/560,723

Atty. Ref.: 3665-166

Amendment After Final rejection

April 28, 2008

## **AMENDMENTS TO THE CLAIMS:**

Amend the claims as follows:

1. (Currently Amended) An isolated nucleic acid that is expressed by human

prostate cancer cells, wherein said nucleic acid comprises selected from the group

consisting of:

(i) the nucleic acid comprising the sequence of SEQ ID NO: 92;

(ii) variants thereof, wherein such variants have a nucleic acid sequence that

is at least 95% identical to the sequence of (i) when aligned without allowing for gaps;

and

(iii) fragments of (i) or (ii) having a size of at least 20 nucleotides in length,

wherein said fragments comprise a portion of the sequence of (i) or (ii) comprising an

exon-exon, exon-intron or intron-intron junction sequence generated by splicing.

2. (Currently Amended) [[The]]A nucleic acid of Claim 1, which comprises at

least a fragment of SEQ ID NO:92 encoding SEQ ID NO:183the nucleic acid sequence

of SEQ ID NO: 92.

Claim 3. (Canceled)

Claims 4-15. (Canceled)

16. (Currently Amended) A diagnostic kit for detection of prostate cancer which

comprises a nucleic acid according to Claim 1 or 2 and a detectable label.

- 2 -

1331701

EINSTEIN et al. Appl. No. 10/560,723 Atty. Ref.: 3665-166 Amendment After Final rejection April 28, 2008

Claim 17. (Canceled)

Claims 18-31. (Canceled)

Claims 32-33. (Canceled)

Claim 34. (Canceled)